Trademark: 87343488
Word
AUREGEN BIOTHERAPEUTICS
Status Date
Monday, February 15, 2021
Filing Date
Tuesday, February 21, 2017
Published for Opposition
Tuesday, November 14, 2017
Abandoned Date
Monday, February 15, 2021
1 Stem cells for research purposes; stem cells for scientific purposes; stem cells for research or scientific purposes; stem cells other than for medical or veterinary purposes; hydrogel polymer edible coatings for tablets; lactic acid polymers; aqueous linear polymer gels; photo curable compositions comprising polymers; chemicals for use in polymerisations; engineered biological tissues and tissue arrays, namely, human and animal organ, connective, epithelial, muscular, and nervous tissues and tissue arrays, for use in scientific and medical research; biologically compatible materials, namely, hydrogels used to create polymeric networks used in the manufacture of living tissue; all the aforementioned for in vivo use in the fields of therapeutic and/or aesthetic treatment
5 Pharmaceutical preparations for use in the field of 3D bio-printing of tissues and organs; preparations based on cellulous nano-fibrils for use in the 3D bio-printing of tissues and organs; tissue-regenerative pharmaceutical preparations; biological implants for skin and cartilage; biological skin and cartilage tissue for implantation; cells for medical use; human allograft tissue; living cells for medical use; implants of living tissues for guided tissue regeneration; implants comprising living tissue; implantable materials of living tissue for use in guided tissue regeneration; skin grafts; surgical implants comprised of living tissues; surgical implants of living tissues grown from stem cells; transdermal patches for use to create skin for prosthetic limbs and for skin grafts; living tissues for transplant; antibodies for use to create skin for prosthetic limbs and for skin grafts; stem cells for medical purposes; engineered biological tissues and organs, namely, human and animal cardiovascular, pulmonary, digestive, hepatobiliary, urological, renal, endocrine, connective, epithelial, muscular, and nervous tissue and organs, for medical purposes; biological molecules to assist in the development of tissue; hemostatic gel matrix preparations for treating wounds; natural biomaterials for augmentation of bone, blood and tissue for medical purposes; processed human donor skin for the replacement of soft tissue; pharmaceutical products for tissue regeneration, for tissue repair, for tissue treatment, whether relating to human or animal tissue; pharmaceutical preparations for the treatment of bone diseases, for cartilaginous diseases, for vascular diseases, for neuronal degeneration, for degeneration of tendons and ligaments, for retinal degeneration, for renal degeneration, degeneration of soft tissue, for diseases with abnormal cell proliferation; natural biomaterials for bone filling; natural biomaterials for filling cartilage; stem cells for medical use; surgical implants of living tissue; surgical cloths for wound protection; surgical implants grown from stem cells; biological tissue cultures for medical use, all the aforementioned for in vivo use in the fields of therapeutic and/or aesthetic treatment
7 Three-dimensional (3D) printers (3D printers); three-dimensional (3D) bioprinters (3D bioprinters); computerized equipment for the generation of three-dimensional shaped parts; machines for manufacturing three dimensional models, namely, computer-aided modeling devices; machines for manufacturing three dimensional (3D) living tissues; machines, namely, three dimensional (3D) bioprinter for the printing of living tissues; cartridges for containing printing material for use with three dimensional printers; cartridges for containing bioprinting material for use with three dimensional printers; printing cartridges for containing biomaterial for use with three dimensional printers; printing cartridges for containing bioink for use with three dimensional printers
9 Laboratory apparatus for fabrication of three-dimensional tissues and organs; biochips for the production of three-dimensional living tissues and organs; bioreactor for cell culturing; bioreactors for laboratory use; bioreactors for research use; cell culture apparatus for laboratory use, namely, cell culture dishes, tissue culture flasks; imaging devices for use in research on biomaterials adapted and used for printing three- dimensional objects for the creation of prosthetic limbs and grafts; laboratory apparatus and instruments for use in research on biomaterials adapted and used for printing three-dimensional objects for the creation of prosthetic limbs and grafts; print heads for inkjet printers; scientific research and laboratory apparatus and instruments for research on biomaterials adapted and used for printing three-dimensional objects for the creation of prosthetic limbs and grafts in the field of cytology; laboratory apparatus and instruments for research on biomaterials adapted and used for printing three-dimensional objects for the creation of prosthetic limbs and grafts for use in biopharmaceutical discovery and development; laboratory apparatus and instruments for research on biomaterials adapted and used for printing three-dimensional objects for the creation of prosthetic limbs and grafts; replacement parts and fittings for all the aforesaid goods; all the aforementioned for in vivo use in the fields of therapeutic and/or aesthetic treatment
10 Surgical, medical, dental apparatus and instruments, including imaging devices, for medical purposes; orthopedic articles, namely, burrs, picks, mirrors, tissue cutters, support bandages, and braces; artificial limbs; artificial surgical implants; bone substitutes for surgical use; fluid injectors for medical purposes; trocars; artificial tissue replacement for restoring, maintaining and /or improving the function of diseased or damaged human or animal tissue; synthetic implants and transplants and synthetic modified implants and transplants, tissue, cells and/or molecules for replacing and/or for supporting the function of missing or damaged body parts; synthetic hard and soft tissue, in particular synthetic bone for transplantation purposes, synthetic bone replacement, cartilage replacement, vessel replacement, tissue replacement and fatty tissue replacement; synthetic modified implants and transplants with endogenous material, tissue, cells or molecules for replacement and/or for supporting the function of missing or damaged body parts, all the aforementioned for in vivo use in the fields of therapeutic and/or aesthetic treatment
40 3D printing services; renting of 3D printers; creation of customized three-dimensional shaped parts using rapid prototyping equipment; 3D bioprinting; bioprinting
42 Technical research in the fields of biomimetics, biomaterials, material adaptation, 3D bioprinting and tissue engineering; research and development of medical devices; research in the field of nanotechnology and nanomaterials; synthetic biology research; robotics research; bioengineering research; nanotherapeutics research; 3D bioprinting research; tissue engineering research; research and development of 3D technology and processes; development of rapid prototyping equipment; technical consultancy relating to rapid prototyping; scientific research consulting in the fields of three-dimensional printing; scientific services relating to the isolation and cultivation of human tissues and cells; scientific and medical research and development in the field of bio-printing; scientific and medical research and development in the field of tissue manufacturing; development and culture of artificial tissues and cells (tissue engineering); tissue engineering services; industrial analysis and research services in the field of tissue engineering research in the fields of regenerative biotherapies, genomics, biotechnology, chemicals and pharmaceuticals, research and testing services in the fields of regenerative biotherapies, genomics, biotechnology, chemicals and pharmaceuticals; research and development of new products for others in the fields of regenerative biotherapies, genomics, biotechnology, chemicals and pharmaceuticals; design and development of computer hardware and software, all the aforementioned for in vivo use in the fields of therapeutic and/or aesthetic treatment
44 Medical services, namely, in the field of gene and cellular immunotherapies and transplantation, monitoring and reporting services; medical treatment services; consulting services in the fields of medical treatment and medicines; human cell and tissue banking services; collection and preservation of human blood and cells for medical use, all the aforementioned for in vivo use in the fields of therapeutic and/or aesthetic treatment
Feb 16, 2021
Abandonment Notice E-Mailed - No Use Statement Filed
Feb 15, 2021
Abandonment - No Use Statement Filed
Jun 4, 2020
Notice Of Approval Of Extension Request E-Mailed
Jun 3, 2020
Extension 5 Granted
May 26, 2020
Extension 5 Filed
May 26, 2020
Teas Extension Received
May 19, 2020
Applicant/Correspondence Changes (Non-Responsive) Entered
May 19, 2020
Teas Change Of Correspondence Received
May 19, 2020
Teas Change Of Domestic Representatives Address
May 19, 2020
Teas Withdrawal Of Attorney Received-Firm Retains
May 19, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
May 19, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
May 19, 2020
Teas Change Of Owner Address Received
Jan 1, 2020
Notice Of Approval Of Extension Request E-Mailed
Dec 30, 2019
Extension 4 Granted
Dec 30, 2019
Extension 4 Filed
Dec 30, 2019
Teas Extension Received
Jul 3, 2019
Notice Of Approval Of Extension Request E-Mailed
Jul 1, 2019
Extension 3 Granted
Jul 1, 2019
Extension 3 Filed
Jul 1, 2019
Teas Extension Received
Jun 17, 2019
Teas Change Of Correspondence Received
Dec 19, 2018
Notice Of Approval Of Extension Request E-Mailed
Dec 17, 2018
Extension 2 Granted
Dec 17, 2018
Extension 2 Filed
Dec 17, 2018
Teas Extension Received
Jun 8, 2018
Notice Of Approval Of Extension Request E-Mailed
Jun 6, 2018
Extension 1 Granted
Jun 6, 2018
Extension 1 Filed
Jun 6, 2018
Teas Extension Received
Mar 14, 2018
Applicant/Correspondence Changes (Non-Responsive) Entered
Mar 6, 2018
Case Assigned To Intent To Use Paralegal
Feb 21, 2018
Teas Post Publication Amendment Received
Jan 9, 2018
Noa E-Mailed - Sou Required From Applicant
Nov 14, 2017
Official Gazette Publication Confirmation E-Mailed
Nov 14, 2017
Published For Opposition
Oct 25, 2017
Notification Of Notice Of Publication E-Mailed
Oct 5, 2017
Approved For Pub - Principal Register
Oct 5, 2017
Examiner's Amendment Entered
Oct 5, 2017
Notification Of Examiners Amendment E-Mailed
Oct 5, 2017
Examiners Amendment E-Mailed
Oct 5, 2017
Examiners Amendment -Written
Sep 25, 2017
Notification Of Non-Final Action E-Mailed
Sep 25, 2017
Non-Final Action E-Mailed
Sep 25, 2017
Non-Final Action Written
Sep 18, 2017
Previous Allowance Count Withdrawn
Sep 5, 2017
Withdrawn From Pub - Og Review Query
Aug 18, 2017
Approved For Pub - Principal Register
Aug 9, 2017
Teas/Email Correspondence Entered
Aug 9, 2017
Correspondence Received In Law Office
Aug 9, 2017
Teas Response To Office Action Received
May 23, 2017
Notification Of Non-Final Action E-Mailed
May 23, 2017
Non-Final Action E-Mailed
May 23, 2017
Non-Final Action Written
May 16, 2017
Assigned To Examiner
May 11, 2017
Preliminary/Voluntary Amendment - Entered
May 3, 2017
Assigned To Lie
Apr 18, 2017
Teas Voluntary Amendment Received
Feb 28, 2017
New Application Office Supplied Data Entered In Tram
Feb 24, 2017
New Application Entered In Tram
Trademark Alertz updated from USPTO on 2030-01-24
